DHC Pediatric Webinar - Updates in Pediatric Psychiatry and Pharmacogenetics

Monday, April 27, 2026, 8:00 AM - Friday, April 27, 2029, 9:00 AM

AMA PRA Category 1 Credits™ (1.00 hours), ANCC Nursing Contact Hours (1.00 hours), ASWB Social Work Credit(s) (1.00 hours), CME-Designated Participation Credit (1.00 hours)

This Pediatric Lecture Series will discuss important pediatric topics that may lead to the improvement of child health from an individual, health care system and/or societal level. This presentation provides information on screening, reporting, diagnosis, treatment, and referral options for pediatric psychiatry and pharmacogenetics.

Presenter

Katherine M. Shea, MD, MPH
Dartmouth Health, Assistant Professor of Psychiatry, Pediatrics
The Dartmouth Institute Associate Program Director, Leadership Preventive Medicine Residency

After graduating from Dartmouth Medical School, Katie completed residencies in psychiatry, child and adolescent psychiatry, and preventive medicine at Dartmouth-Hitchcock Medical Center. She now serves as the physician lead for Dartmouth Health Children’s Pediatric Collaborative Care Program, which provides timely, coordinated, and high quality behavioral health care to children and families within pediatric primary care clinics. As a coach in the Leadership Preventive Medicine Residency, Katie teaches quality improvement to residents across multiple specialties at DHMC and Concord Hospital. She values practicing in Northern New England, where she spends her free time skiing, hiking, and mountain biking.

1. Identify clinically actionable drug-genotypes relationships for psychiatric medications commonly prescribed in primary care.
2. Recognize non-genetic factors that may influence response and tolerability of psychiatric medications.
3. Develop appropriate approaches to patient and family requests for pharmacogenomic testing.

In support of improving patient care, Dartmouth Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

American Medical Association (AMA)

Dartmouth Health designates this Enduring Material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

American Nurses Credentialing Center (ANCC)

Dartmouth Health designates this Enduring Material for a maximum of 1.00 ANCC contact hours.

Association of Social Work Boards (ASWB)

As a Jointly Accredited Organization, Dartmouth Health is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this course receive 1.0 general continuing education credits.

Social Worker Account Setup

If you wish to apply for ASWB credit, you will need to enter your license number in your CE Profile by following these steps:

1. Log in to Dartmouth Health's CE portal (https://dh.cloud-cme.com).

2. From the My Account Menu, select Profile.

3. Ensure your degree and profession are accurately reflected.

4. Enter the state license type, License #, and Expiration date.

5. Scroll down to the bottom of the screen and click Submit.

All other learners may claim CME-designated participation credit. Consult your professional licensing board regarding the applicability and acceptance of CME-designated participation credit for programs certified for credit by organizations accredited by Joint Accreditation for Interprofessional Education.

Registration/Requirements for Successful Completion
You may claim credit for successful completion of this online course. In order to claim credit, you must follow these steps:

1. Click the Register tab above. If you are not logged into your account, you will need to log in. Use the Forgot Your Password? button if you need to reset your password.

2. Register for the activity.

3. Click the Content/Tests tab and then View Content to view the recording. View the entire presentation.

4. Complete the Post-Test (attestation - return to the Content/Tests tab to find it).

5. Click the Complete Evaluation button, or click My Account in the menu bar; then click Evaluations.

6. Complete and Submit the Evaluation.

Bibliographic Material

• Altar, C., Carhart, J., Allen, J. et al. Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes. Pharmacogenomics J. 2015;15:443–451.

• Bousman CA, Eyre HA. "Black box" pharmacogenetic decision-support tools in psychiatry. Braz J Psychiatry. 2020;42(2):113-115.

• Bousman CA, Dunlop BW. Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support tools. Pharmacogenomics J. 2018;18(5):613-622.

• Goetz MP, Sangkuhl K, Guchelaar HJ, Schwab M, Province M, Whirl-Carrillo M, Symmans WF, McLeod HL, Ratain MJ, Zembutsu H, Gaedigk A, van Schaik RH, Ingle JN, Caudle KE, Klein TE. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Clin Pharmacol Ther. 2018;103(5):770-777

• Klomp SD, Manson ML, Guchelaar H-J, Swen JJ. Phenoconversion of Cytochrome P450 Metabolism: A Systematic Review. Journal of Clinical Medicine. 2020; 9(9):2890.

• Malik S, Verma P, Ruaño G, Al Siaghy A, Dilawar A, Bishop JR, Strawn JR, Namerow LB. Pharmacogenetics in Child and Adolescent Psychiatry: Background and Evidence-Based Clinical Applications. J Child Adolesc Psychopharmacol. 2024;34(1):4-20.

• Namerow LB, Ramsey LB, Malik S, Cortese S, Strawn JR. Editorial: Beyond Red Light, Green Light: Examining the Role of Pharmacogenomics in Evidence-Based Care in Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry. 2022;61(1):29-31.

• Namerow LB, Strawn JR. The Pharmacogenetic Journey in Child and Adolescent Psychopharmacology: Are We There Yet? J Child Adolesc Psychopharmacol. 2024;34(1):1-3.

• Ramsey LB, Namerow LB, Bishop JR, Hicks JK, Bousman C, Croarkin PE, Mathews CA, Van Driest SL, Strawn JR. Thoughtful Clinical Use of Pharmacogenetics in Child and Adolescent Psychopharmacology. J Am Acad Child Adolesc Psychiatry. 2021;60(6):660-664.

• Poweleit EA, Aldrich SL, Martin LJ, Hahn D, Strawn JR, Ramsey LB. Pharmacogenetics of Sertraline Tolerability and Response in Pediatric Anxiety and Depressive Disorders. J Child Adolesc Psychopharmacol. 2019;29(5):348-361.

• Spina E, Scordo MG, Arrigo C. Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol. 2003;17:517-538.

• Strawn JR, Mills JA, Schroeder H, Mossman SA, Varney ST, Ramsey LB, Poweleit EA, Desta Z, Cecil K, DelBello MP. Escitalopram in Adolescents With Generalized Anxiety Disorder: A Double-Blind, Randomized, Placebo-Controlled Study. J Clin Psychiatry. 2020;81(5):20m13396.

• Tran TTV, Tayara H, Chong KT. Artificial Intelligence in Drug Metabolism and Excretion Prediction: Recent Advances, Challenges, and Future Perspectives. Pharmaceutics. 2023; 15(4):1260.

• Vande Voort JL, Orth SS, Shekunov J, Romanowicz M, Geske JR, Ward JA, Leibman NI, Frye MA, Croarkin PE. A Randomized Controlled Trial of Combinatorial Pharmacogenetics Testing in Adolescent Depression. J Am Acad Child Adolesc Psychiatry. 2022;61(1):46-55.

• Vaughn SE, Strawn JR, Poweleit EA, Sarangdhar M, Ramsey LB. The Impact of Marijuana on Antidepressant Treatment in Adolescents: Clinical and Pharmacologic Considerations. J Pers Med. 2021;11(7):615.

• Zhou Y, Lauschke VM. The genetic landscape of major drug metabolizing cytochrome P450 genes-an updated analysis of population-scale sequencing data. Pharmacogenomics J. 2022;22(5-6):284-293.
  
  

Provider Contact Information
Provider contact information for questions regarding accreditation of the activity:

Center for Learning and Professional Development
ACE Office
Dartmouth Health
[email protected]

You are not logged in.

Please click the button below to login or create a new account before continuing.

Mitigation of Relevant Financial Relationships

Dartmouth Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education.  Any individuals in a position to control the content of a CE activity, including planners, faculty, authors, or others are required to disclose all financial relationships with ineligible companies^.  All relevant financial relationships have been mitigated prior to the commencement of the activity.

^Ineligible Company is any entity whose primary business purpose is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.